Published in Blood Weekly, May 29th, 1995
In the study, rhIL-11 restored platelets in thrombocytopenic (platelet-depleted) patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions when compared to patients on placebo.
Based on this favorable outcome, Genetics Institute also announced that it plans to begin a Phase III study of rhIL-11 by the end of 1995. In addition, the company expects to have results from two additional Phase II studies later in 1995.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.